PIPELINE

R&D Programs

logo Vaxdyn blanco-verde

MultiVAX

Vaxdyn and the University of Latvia have obtained funding from the EUROSTARS program to prepare prevention strategies for diseases caused by antibiotic-resistant bacteria.

The research consortium led by Vaxdyn, comprising the vaccine company and the University of Latvia, has been awarded a grant of 647,000 euros to develop the clinical and commercial vaccination strategy against Klebsiella pneumoniae and Acinetobacter baumannii. These are two of the main antibiotic-resistant bacteria for which the World Health Organization has identified an urgent need for preventive vaccines.

The grant to Vaxdyn, amounting to 397,000 euros, was approved in the Interempresas call of CDTI, following a positive decision by the European Commission. The project has been funded by CDTI and the Ministry of Science and Innovation of Spain.

The project will involve an assessment of the epidemiology of the population affected by these bacteria at the Paul Stradins University Hospital in Riga, Latvia’s reference hospital. Vaxdyn will confirm that the circulating bacteria among patients are covered by the immunity generated by the K-Vax vaccine under development, which is showing universal coverage. The project’s most ambitious goal is to define the strategy for conducting clinical efficacy trials of the vaccine and the strategy for using the vaccine once approved to create the greatest value for society. The project, which will be carried out between 2023 and 2026, is led by Vaxdyn’s director, Dr. Juan José Infante, and the renowned infectious disease expert Dr. Uga Dumpis, head of infectious diseases at Paul Stradins Hospital.

Funded by the CDTI

This project has received funding from the ‘Eurostars-International Intercompany’ program with co-financing from CDTI and the European Union’s ‘Horizon Europe’ Research and Innovation Framework Program.

AMReady

AMReady (2021-2024): “Development and manufacturing of vaccines for alleviation and preparedness fot anti-microbial resistance global health crisis” is a project founded by the competitive program Líneas Estratégicas de Colaboración Público-Privada 2021 of the State Research Agency of the Spanish Ministry of Science and Innovation, in the Recovery and Resilience Plan co- financed with Next Generation UE Funds.

AMReady is a very complete consortium of institutions led by Vaxdyn and formed by the Barcelona-based international pharmaceutical manufacturer Laboratorio Reig Jofre and top groups in immunology and infectious disease of the National Microbiology Center (CNM) of the Spanish Institutes of Health “Carlos III” (ISCIII) in Madrid, the University of Cordoba and the Institute of Parasitology and Biomedicine “López Neyra” of the CSIC in Granada.

In this project we are providing solutions in two major fronts. First, the major source of antibiotic resistance is the extensive use of antibiotics for prevention of respiratory diseases in livestock. And second, there are human populations with recurrent infections now caused by antibiotic-resistant pathogens.



STOPINFECTIONS

STOPINFECTIONS (2020-2023) is a research project funded by the competitive program RETOS-COLABORACION 2019 of the State Research Agency of the Spanish Ministry of Science and Innovation. The goal of the project is to execute activities to support taking Vaxdyn’s technology for vaccine development to file a permit to enter clinical phase for prevention of pneumonia resistant to antibiotics.

Execution of STOPINFECTIONS in 2020-2022 is made by a consortium led by Vaxdyn. The partners are ISCIII in Madrid, Laboratorios Reig Jofré, and Leitat Technological Center (Barcelona).

Previous Programs

The project finished with completion of preclinical research of AcinetoVax, the first universal vaccine against drug resistant Acinetobacter baumannii (VXD-01). The research performed allowed conversion of a single product into a technological platform to deliver multivalent vaccine candidates against Gram-negative bacteria. These results made possible to execute the business plan of Vaxdyn and attract private investors that today are making possible to deliver vaccines for tackling antibiotic-resistant infections.

Execution was made by a consortium led by Vaxdyn. The partners were the Andalusian Healthcare Service, the University of Seville, Laboratorios Reig Jofré (Barcelona), and Leitat Technological Center (Barcelona).

The project finished with experimental trials in porcine of vaccines to prevent respiratory viral and bacterial diseases in piglets that are currently treated with antibiotics, leading to the appearance and spread of antibiotic-resistant pathogens. Vaxdyn tested its technological platform for raising immunity in pigs for applications in the veterinary industry, leading a consortium formed by the following partners: the biotech group ADL Bionatur Solutions, who tested viral subunit vaccines; the Institute of Parasitology and Biomedicine “López Neyra” of the CSIC in Granada, who carried mice immunological assays; the biotech company Bionanoplus (Pamplona, Spain), who formulated the vaccine active principles to test intranasal versus intramuscular delivery; and the Faculty of Veterinary Sciences of the University of Córdoba, who managed the experimental work on pigs.

Acinetobacter baumannii. The company obtained a battery of monoclonal antibodies and tested them for passive immunization of murine models. Other partners included the Andalusian biotechnology companies Bionaturis Group and Vivacell.

The project was funded by the competitive FEDER-INTERCONNECTA 2015 program of the Center for Industrial and Technological Development (CDTI) of the government of Spain, with the support of funds of the ERDF Programme of the European Union.

Within the project, Vaxdyn compared different technological platforms to deliver a vaccine against multi-drug resistant Acinetobacter baumannii and began to explore how the immunity raised by its first vaccine candidate against A. baumannii could lead to development of injectable sera to treat infections already established in the host. Other partners included the Andalusian biotechnology companies Bionaturis Group, Biomedal, and Althea.

The project was funded by the competitive FEDER-INTERCONNECTA 2013 program of the Center for Industrial and Technological Development (CDTI) of the government of Spain, with the support of funds of the ERDF Programme of the European Union.

This project led to Vaxdyn being established as a spin-off from the Institute of Biomedicine of Seville (IBiS) for development of vaccine candidates against antibiotic-resistant infections. The project allowed completion the technology transfer process of technologies matured at the Infectious Diseases Group of the IBiS, led by Dr. Jerónimo Pachón and Dr. Michael McConnell, to Vaxdyn.

Funding of this project allowed to achieve the first business milestone of Vaxdyn in its road to take to the final users preventive vaccines for ameliorating the global health crisis caused by superbacteria. The company acquired its technology that would be further developed until today.

CONTACT

Vaxdyn

Supported by

CONTACT US


Vaxdyn logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.